As of July 1, 2026, the MDLs case count has risen to 3,848
Appeal Lost Coverage Bridget Roberts, 37, was reapproved for Zepbound by remaining persistent
Common complaints include nausea, vomiting, and sometimes diarrhea or constipation
[1] [2] Additional monitoring considerations include: For patients using Zepbound, monitoring for new or worsening depression, suicidal thoughts, or unusual mood changes For women of reproductive age, counseling about potential reduced effectiveness of oral contraceptives
No contraindication exists for concurrent use with anticoagulants including warfarin, DOACs (apixaban, rivaroxaban, edoxaban, dabigatran), or low-molecular-weight heparins